Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.

@article{Shinoki2012SafetyAR,
  title={Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.},
  author={Toshihiko Shinoki and Ryoki Hara and Utako Kaneko and Takako Miyamae and Tomoyuki Imagawa and Masaaki Mori and Shunpei Yokota},
  journal={Modern rheumatology},
  year={2012},
  volume={22 6},
  pages={871-6}
}
OBJECTIVE We investigated the safety and efficacy of administering influenza vaccines to patients with systemic-onset juvenile idiopathic arthritis (sJIA) treated with tocilizumab. PATIENTS AND METHODS The subjects were 27 sJIA patients treated with tocilizumab and 17 healthy age- and sex-matched volunteers. Serum samples were collected prior to and 4-7 weeks after vaccination. Hemagglutination inhibition values of the vaccine were taken as the antibody titers. The duration of tocilizumab… CONTINUE READING
14 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Analysis of the incidence of influenza, the response of influenza vaccination and the effectiveness of anti-influenza drugs in the 2007-2008 winter season in Japan (in Japanese)

  • N Kawai, H Ikematsu, N Iwaki
  • Japan Med J 2008;4416:70–5
  • 2008
1 Excerpt

The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination

  • LB Gelinck, AE van der Bijl, WE Beyer
  • Ann Rheum Dis
  • 2008
3 Excerpts

Similar Papers

Loading similar papers…